813 patients enrolled

203 patients
Placebo

- 15 patients (7%) discontinued:
  - Protocol deviation: 2
  - Noncompliance: 1
  - Adverse event: 1
  - Withdraw consent: 7
  - Alternative therapy: 2
  - Lost to follow-up: 1
  - Other: 1

- 188 patients (93%) completed 24 weeks

204 patients
AMG 108 – 50 mg

- 24 patients (12%) discontinued:
  - Protocol deviation: 1
  - Adverse event: 2
  - Withdraw consent: 13
  - Alternative therapy: 6
  - Lost to follow-up: 2

- 180 patients (88%) completed 24 weeks

203 patients
AMG 108 – 125 mg

- 24 patients (12%) discontinued:
  - Protocol deviation: 3
  - Noncompliance: 1
  - Adverse event: 3
  - Withdraw consent: 11
  - Alternative therapy: 3
  - Lost to follow-up: 1
  - Other: 2

- 179 patients (88%) completed 24 weeks

203 patients
AMG 108 – 250 mg

- 21 patients (10%) discontinued:
  - Protocol deviation: 2
  - Noncompliance: 2
  - Adverse event: 2
  - Withdraw consent: 7
  - Alternative therapy: 4
  - Lost to follow-up: 2
  - Other: 2

- 182 patients (90%) completed 24 weeks